BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through...
BioCentury | Nov 17, 2017
Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round...
BioCentury | Nov 15, 2017
Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
Items per page:
1 - 3 of 3
BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through...
BioCentury | Nov 17, 2017
Financial News

Venture roundup: ImmusanT, Locus

On Nov. 14, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round...
BioCentury | Nov 15, 2017
Financial News

Venture Roundup: ImmusanT, Locus

On Tuesday, autoimmune company ImmusanT Inc. (Cambridge, Mass.) and antimicrobial play Locus Biosciences Inc. (Research Triangle Park, N.C.) announced venture financings totaling nearly $60 million. ImmusanT raised $40 million in a series C round led...
Items per page:
1 - 3 of 3